SUNNYVALE, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months and full year ended December 31, 2019. Recent Highlights Revenue of $18.6 million for the […]
Author: Ken Dropiewski
Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
– NEXLIZET Lowered LDL-C by 38 Percent Compared to Placebo when Added on to Maximally Tolerated Statins – – First Non-Statin, LDL-Cholesterol Lowering Combination Medicine Ever Approved – – Esperion’s Second Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. Following NEXLETOL™ (bempedoic acid) Tablet Approval on February 21, […]
Otitopic Advances Asprihale® Into Pivotal PK/PD Study
Asprihale® is intended for emergency treatment to reduce the risk of vascular mortality in patients with suspected acute myocardial infarction (MI). LOS ANGELES–(BUSINESS WIRE)–Otitopic today announces that it is advancing towards its pivotal PK/PD study following discussions with the FDA. The randomized pivotal study, which is expected to initiate in the […]
NeuroVasc Secures $34 Million in Funding to Support Clinical Trials and Product Development
Neurovascular Device Portfolio Development and Global Clinical Trials IRVINE, Calif.–(BUSINESS WIRE)–NeuroVasc Technologies, Inc. announced that it has entered into a strategic partnership with the Wego Group that includes $34 million in funding to support the company’s product portfolio development and global clinical trial program. With a focus on novel catheter-based […]
Ra Medical Systems Announces Enrollment of First Patient in Pivotal Atherectomy Clinical Study
CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces enrollment of the first patient in its pivotal study to evaluate the safety and effectiveness of the DABRA excimer laser system for use as an […]
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue without Changes Topline Results Expected in Q4 2020 THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 26, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN), Cytokinetics, Incorporated (NASDAQ:CYTK) and Servier today announced that the Data Monitoring Committee (DMC) […]
Gore Innovation Center Announces Collaboration With Robotics Startup Moray Medical
Startups join Gore Innovation Center to bring new technologies to market. SANTA CLARA, Calif., Feb. 26, 2020 /PRNewswire/ — The Gore Innovation Center today announced a collaboration with Moray Medical, a 2-year-old startup developing precision automated delivery systems for endovascular procedures. The Gore Innovation Center collaboration with Moray Medical is aimed at fundamentally improving the […]
Amarin Reports Record Fourth Quarter and Full Year 2019 Financial Results and Provides Update on Operations
Record Revenue of $429.8 Million and $143.3 Million for Full Year and Fourth Quarter 2019 Launch Commenced of VASCEPA® as First and Only Drug with Its New Cardiovascular Risk Reduction Indication Management to Host Conference Call at 4:30 p.m. ET Today DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) — […]
BioSig Announces Closing of Public Offering of Common Stock
Westport, CT, Feb. 25, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the closing and funding of […]
Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights
CONSHOHOCKEN, Pa., Feb. 26, 2020 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2019 financial results and highlights: “Madrigal made significant progress during 2019 in executing our business strategy and advancing the development of resmetirom. We initiated two Phase 3 studies in NASH: […]



